Literature DB >> 15979725

Identifying "paradigm failures" contributing to treatment-resistant depression.

G B Parker1, G S Malhi, J G Crawford, M E Thase.   

Abstract

BACKGROUND: "Treatment resistant depression" is likely to emerge from a number of factors, including application of the wrong diagnostic and treatment models.
METHOD: Current paradigms for managing both depression and treatment resistant depression are considered. We then examine the prevalence of a set of paradigm failures that appeared to contribute to treatment resistant depression in outpatients of a tertiary referral Mood Disorders Unit.
RESULTS: Six illustrative paradigm failures are described and their frequencies within the clinical sample reported. Identified paradigm failures were diagnosing and/or managing a non-melancholic condition as if it were melancholic depression, failure to diagnose and manage bipolar disorder, psychotic depression or melancholic depression, misdiagnosing secondary depression and failure to identify organic determinants.
CONCLUSION: We suggest that the identification of such "paradigm failures"--and of others that can be assumed to operate--has the potential to enrich the assessment and management of depressed patients, and reduce the prevalence of treatment resistance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15979725     DOI: 10.1016/j.jad.2005.02.015

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  10 in total

1.  Association between bipolar spectrum features and treatment outcomes in outpatients with major depressive disorder.

Authors:  Roy H Perlis; Rudolf Uher; Michael Ostacher; Joseph F Goldberg; Madhukar H Trivedi; A John Rush; Maurizio Fava
Journal:  Arch Gen Psychiatry       Date:  2010-12-06

2.  Broadening the diagnosis of bipolar disorder: benefits vs. risks.

Authors:  Stephen M Strakowski; David E Fleck; Mario Maj
Journal:  World Psychiatry       Date:  2011-10       Impact factor: 49.548

3.  Bipolar-I depression outpatient treatment quality and costs in usual care practice.

Authors:  Alisa B Busch; Richard G Frank; Gary Sachs
Journal:  Psychopharmacol Bull       Date:  2008

4.  Integrating EMDR into an evolutionary-based therapy for depression: a case study.

Authors:  Valery Krupnik
Journal:  Clin Case Rep       Date:  2015-02-19

5.  Analysis of the presence or absence of atrophy of the subgenual and subcallosal cingulate cortices using voxel-based morphometry on MRI is useful to select prescriptions for patients with depressive symptoms.

Authors:  Akira Niida; Richi Niida; Hiroshi Matsuda; Makoto Motomura; Akihiko Uechi
Journal:  Int J Gen Med       Date:  2014-12-03

6.  High-dose antidepressants affect near-infrared spectroscopy signals: A retrospective study.

Authors:  Akihiro Takamiya; Jinichi Hirano; Yuki Ebuchi; Satoyuki Ogino; Kenichi Shimegi; Hiroyuki Emura; Kyoko Yonemori; Akiko Shimazawa; Gentaro Miura; Ayako Hyodo; Sari Hyodo; Tunetaka Nagai; Madoka Funaki; Masako Sugihara; Mitsuhiro Kita; Bun Yamagata; Masaru Mimura
Journal:  Neuroimage Clin       Date:  2017-02-13       Impact factor: 4.881

Review 7.  Management of Treatment-Resistant Depression: Challenges and Strategies.

Authors:  Daphne Voineskos; Zafiris J Daskalakis; Daniel M Blumberger
Journal:  Neuropsychiatr Dis Treat       Date:  2020-01-21       Impact factor: 2.570

8.  Comparison of hypothalamo-pituitary-adrenal function in treatment resistant unipolar and bipolar depression.

Authors:  Kalypso Markopoulou; Susanne Fischer; Andrew Papadopoulos; Lucia Poon; Lena J Rane; Abebaw Fekadu; Anthony J Cleare
Journal:  Transl Psychiatry       Date:  2021-04-26       Impact factor: 6.222

9.  The treatment of nonmelancholic depression: when antidepressants fail, does psychotherapy work?

Authors:  Gordon Parker; Rebecca Graham; Elizabeth Sheppard
Journal:  Can J Psychiatry       Date:  2014-07       Impact factor: 4.356

10.  Standardisation framework for the Maudsley staging method for treatment resistance in depression.

Authors:  Abebaw Fekadu; Jacek G Donocik; Anthony J Cleare
Journal:  BMC Psychiatry       Date:  2018-04-11       Impact factor: 3.630

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.